| Dr Christopher J Pole, MD | |
|
5520 College Blvd, Ste 201, Overland Park, KS 66211-1630 | |
| (913) 491-3737 | |
| (491) 469-6686 |
| Full Name | Dr Christopher J Pole |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 16 Years |
| Location | 5520 College Blvd, Overland Park, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285883231 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 04-35809 (Kansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cokingtin Eye Center Pa | 9739182841 | 8 |
| Cokingtin Eye Center Pa | 9739182841 | 8 |
News Archive
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
A shared set of systems in the brain may play an important role in controlling the retrieval of facts and personal memories utilized in everyday life, new research shows.
Case Western Reserve University (CWRU) said today that it received a $250,000 challenge grant from Johnson & Johnson Services, Inc. through The Johnson & Johnson Corporate Office of Science and Technology (COSAT), and its affiliates. The University will utilize this research grant to support science, medicine and engineering projects to improve human health.
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
A team led by scientists from The Scripps Research Institute has discovered a genetic cause of progressive hearing loss. The findings will help scientists better understand the nature of age-related decline in hearing and may lead to new therapies to prevent or treat the condition.
› Verified 8 days ago
| Entity Name | Cokingtin Eye Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477511335 PECOS PAC ID: 9739182841 Enrollment ID: O20060810000196 |
News Archive
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
A shared set of systems in the brain may play an important role in controlling the retrieval of facts and personal memories utilized in everyday life, new research shows.
Case Western Reserve University (CWRU) said today that it received a $250,000 challenge grant from Johnson & Johnson Services, Inc. through The Johnson & Johnson Corporate Office of Science and Technology (COSAT), and its affiliates. The University will utilize this research grant to support science, medicine and engineering projects to improve human health.
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
A team led by scientists from The Scripps Research Institute has discovered a genetic cause of progressive hearing loss. The findings will help scientists better understand the nature of age-related decline in hearing and may lead to new therapies to prevent or treat the condition.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher J Pole, MD 5520 College Blvd, Ste 201, Overland Park, KS 66211-1630 Ph: (913) 491-3737 | Dr Christopher J Pole, MD 5520 College Blvd, Ste 201, Overland Park, KS 66211-1630 Ph: (913) 491-3737 |
News Archive
Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.
A shared set of systems in the brain may play an important role in controlling the retrieval of facts and personal memories utilized in everyday life, new research shows.
Case Western Reserve University (CWRU) said today that it received a $250,000 challenge grant from Johnson & Johnson Services, Inc. through The Johnson & Johnson Corporate Office of Science and Technology (COSAT), and its affiliates. The University will utilize this research grant to support science, medicine and engineering projects to improve human health.
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
A team led by scientists from The Scripps Research Institute has discovered a genetic cause of progressive hearing loss. The findings will help scientists better understand the nature of age-related decline in hearing and may lead to new therapies to prevent or treat the condition.
› Verified 8 days ago
Dr. Richard Noxon Barr, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: #20 Wycklow, Overland Park, KS 66207 Phone: 913-649-1277 | |
Mr. William N Rosenthal, M.D.F.A.C.S. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10740 Nall Avenue, Suite 220, Overland Park, KS 66211 Phone: 913-663-5900 Fax: 913-663-5902 | |
Dr. Timothy B Cavanaugh, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6200 W 135th St, Suite 300, Overland Park, KS 66223 Phone: 913-897-9200 Fax: 913-897-9233 | |
Austin Andersen, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 11121 W 95th St, Professional Eyecare, Overland Park, KS 66214 Phone: 913-492-7728 Fax: 913-492-5217 | |
Jason E Stahl, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 8300 College Blvd., Suite 201, Overland Park, KS 66210 Phone: 913-491-3330 Fax: 913-491-9650 | |
Jemshed A Khan, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9650 Nall Ave, Overland Park, KS 66207 Phone: 913-696-1154 Fax: 913-696-0984 | |
Ann C Stechschulte, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7200 W 129th St, Overland Park, KS 66213 Phone: 913-897-9299 Fax: 913-897-3031 |